(Total Views: 307)
Posted On: 02/09/2021 11:42:29 AM
Post# of 36568
".isn't that what generex is doing????"
I would argue no.
1) The key part of GNBT is its core patented technological advantage which is its Li-key technology.
"Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation."
2) Oragenics doesn't own the "stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health," it is licensing the technology from the NIH. How will that play out in terms of revenue? Is it a royalty deal?
3) Another great aspect of GNBT's "Complete Vaccine" is that they partnered with Epivax which allowed GNBT to find several protein fragments that appear to be conserved among the different SARS-CoV-2 mutants. Creating a vaccine using a whole spike protein could lead to an ineffective vaccine due to mutations. Additionally, the company pointed out that whole spike proteins used in vaccines could lead to harmful events such as cytokine storms.
I would argue no.
1) The key part of GNBT is its core patented technological advantage which is its Li-key technology.
"Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular, the Ii-Key ensures potent activation of CD4+ T cells, which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation."
2) Oragenics doesn't own the "stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health," it is licensing the technology from the NIH. How will that play out in terms of revenue? Is it a royalty deal?
3) Another great aspect of GNBT's "Complete Vaccine" is that they partnered with Epivax which allowed GNBT to find several protein fragments that appear to be conserved among the different SARS-CoV-2 mutants. Creating a vaccine using a whole spike protein could lead to an ineffective vaccine due to mutations. Additionally, the company pointed out that whole spike proteins used in vaccines could lead to harmful events such as cytokine storms.
(7)
(0)
